Ecopipam

Phase 3Small molecule

EEmalex Biosciences Inc.

Ecopipam is one of 34 small molecule programs targeting Tourette syndrome. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Tourette SyndromeActive, not recruiting

StutteringActive, not recruiting

Self-Injurious BehaviorActive, not recruiting

Tourette SyndromePhase 2

Active, not recruiting

StutteringPhase 2

Active, not recruiting

Self-Injurious BehaviorPhase 3

Active, not recruiting

Competition

Competitive Landscape

33 competitors in Tourette Syndrome

#DrugCompanyPhaseTrials

Epidiolex

Jazz Pharmaceuticals

Approved

—2

Marinol

Alnylam Pharmaceuticals

Approved

—3

Rilutek

AAzurity Pharmaceuticals

Approved

1 4

Abilify

Otsuka

Approved

—5

Bendopa

MMerz Pharmaceuticals GmbH

Haldol

Strattera

Intuniv

Topamax

2 10

Mirapex

Boehringer Ingelheim

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 3Active, not recruiting

Adolescent

NCT06021522

Clinical

Trials by Indication[1]

Tourette syndrome2 trials

Ecopipam Tablets to Study Tourette Syndrome in Children and Adolescents - Open Label Extension

Completed·EEmalex Biosciences Inc.·Phase 2·NCT04114539·124 enrolled

Ecopipam Treatment of Tourette Syndrome

Completed·PPsyadon Pharma·Phase 1/2·NCT01244633·18 enrolled

Tourette's Syndrome2 trials

Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years

Completed·EEmalex Biosciences Inc.·Phase 2·NCT02102698·40 enrolled

Ecopipam Tablets to Study Tourette's Syndrome in Children and Adolescents

Completed·EEmalex Biosciences Inc.·Phase 2·NCT04007991·153 enrolled

Stuttering2 trials

Efficacy and Tolerability of Ecopipam in Adults With Childhood Onset Fluency Disorder (Stuttering).

Unknown status·GGerald Maguire, MD·Phase 2/3·NCT02909088·10 enrolled

Effects of Ecopipam or Placebo in Adults With Stuttering (Speak Freely)

Completed·EEmalex Biosciences Inc.·Phase 2·NCT04492956·68 enrolled

Interaction1 trial

Drug Interaction Study

Completed·EEmalex Biosciences Inc.·Phase 1·NCT06194864·45 enrolled

Adolescent1 trial

A Study to Evaluate Long-term Safety of Ecopipam Tablets in Children, Adolescents and Adults With Tourette's Disorder

Active, not recruiting·EEmalex Biosciences Inc.·Phase 3·NCT06021522·150 enrolled

5 more indications

Tics1 trial

Food-effect Study of Ecopipam Pharmacokinetics

Completed·EEmalex Biosciences Inc.·Phase 1·NCT06669091·25 enrolled

Self-injurious behavior1 trial

Ecopipam Treatment of Self-Injurious Behavior in Subjects With Lesch-Nyhan Disease

Terminated·EEmalex Biosciences Inc.·Phase 3·NCT01751802·9 enrolled

Drug Metabolism1 trial

Drug-Drug Interaction Study to Evaluate the Effects of Ecopipam on the Pharmacokinetics of Multiple Substrates for Drug Metabolism and Transport

Completed·EEmalex Biosciences Inc.·Phase 1·NCT05334108·56 enrolled

Restless Leg Syndrome1 trial

Treatment of Restless Leg Syndrome (RLS) Augmentation With Ecopipam, a D1 Specific Antagonist

Unknown status·WWilliam Ondo, MD·Phase 1/2·NCT03218969·10 enrolled

Unspecified2 trials

Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble

Completed·EEmalex Biosciences Inc.·Phase 2·NCT01215357·34 enrolled

Safety and Tolerability of the D1 Dopamine Receptor Antagonist Ecopipam in Patients With Lesch-Nyhan Disease

Completed·PPsyadon Pharma·Phase 1·NCT01065558·5 enrolled

Sources

References

[1]
ClinicalTrials.gov — 14 trial records for Ecopipam. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Ecopipam compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Ecopipam. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Emalex Biosciences Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: EEmalex Biosciences Inc.

Ecopipam

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Tourette syndrome2 trials

Tourette's Syndrome2 trials

Stuttering2 trials

Interaction1 trial

Adolescent1 trial

Tics1 trial

Self-injurious behavior1 trial

Drug Metabolism1 trial

Restless Leg Syndrome1 trial

Unspecified2 trials

References

Drug Info

Quick Facts

Related News